OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
ABCD ScoreAdjusted Body WeightBody Mass IndexDiaRem ScoreIdeal Weight & Excess Weight Loss

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Dosing of hydrophilic medications in obese patients (e.g., Aminoglycosides).
  • Nutritional assessment and calorie requirement calculations in patients with BMI > 30 kg/m2.
  • Initial ventilator setting calculations when Ideal Body Weight (IBW) may lead to under-ventilation in significant obesity.
  • Estimation of metabolically active tissue mass in morbidly obese individuals.

Inclusion Criteria

Intended for patients whose Actual Body Weight (ABW) exceeds their Ideal Body Weight (IBW) by more than 20% or if BMI > 30 kg/m2.

CLINICAL INSIGHT

How it Works

The AjBW Formula

Standard Component Formulas

IBW (Male)
IBW (Female)
Correction Factor

Physiological Rationale

Adjusted body weight accounts for the fact that adipose tissue is not as metabolically active or vascularized as lean body mass. The 0.4 (40%) correction factor estimates the additional volume of distribution and metabolic demand contributed by excess adipose tissue without assuming it behaves like muscle or organ tissue.

CLINICAL INSIGHT

Practical Pearls

Critical Dosing Insights

  • Aminoglycosides: AjBW is the gold standard for Gentamicin/Tobramycin to prevent nephrotoxicity while ensuring therapeutic levels.
  • Acyclovir: Frequently used for IV dosing in obesity to avoid renal crystallization.
  • Avoid in LMWH: Low Molecular Weight Heparin (Enoxaparin) is typically dosed based on Actual Body Weight (ABW), not AjBW.

Pitfalls & Variations

  • Correction Factor variation: Some pharmacopeias use 0.25 (25%) for specific nutritional settings; 0.4 is the standard for critical care and pharmacy.
  • BMI < 25: Do not use AjBW; utilize ABW as AjBW will paradoxically reduce the calculated weight below the actual weight.
  • Propofol/Fentanyl: Use Lean Body Mass (LBM) or Total Body Weight (TBW) based on the specific anesthetic goal (induction vs. maintenance).
CLINICAL INSIGHT

Next Steps

Application Steps

  • Compare ABW to IBW. If ABW > 1.2 × IBW, proceed with AjBW calculation.
  • Apply calculated AjBW to the specific drug monograph instructions.
  • Order baseline Creatinine for all medications requiring AjBW dosing.
  • Monitor Therapeutic Drug Levels (TDM) frequently as volume of distribution (Vd) is highly variable in obesity.

Related Calculators

CLINICAL INSIGHT

Evidence Base

Foundational Studies

Influence of weight on aminoglycoside pharmacokinetics in morbidly obese patients.

Bauer LA, et al.Eur J Clin Pharmacol.1983

Nutritional Consensus

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient.

ASPEN Board of Directors.JPEN J Parenter Enteral Nutr.2016
CLINICAL INSIGHT

Background

The Obesity Paradox in Pharmacy

Adjusted Body Weight emerged from clinical pharmacy research in the late 1970s and early 80s. Clinicians observed that dosing based on Actual Body Weight led to toxic levels of hydrophilic drugs, while dosing on Ideal Body Weight resulted in treatment failure. The "40% rule" was the mathematical compromise that best fit observed serum concentrations.

Adjusted Body Weight

Clinical Standard: Calculates Ideal Body Weight (Devine Formula) and Adjusted Body Weight for drug dosing in obese patients.

cm
kg

Awaiting assessment

Based on the Devine Formula